Patient distribution in each category
| . | Phase I (n = 60) No. (%) . | Phase II (n = 95) No. (%) . | Phase III (n = 23) No. (%) . |
|---|---|---|---|
| Treatment group | |||
| Novel SA | 1258 (70) | 2067 (54) | 277 (10) |
| CC | 193 (11) | 1315 (34) | 1574 (57) |
| SA + CC | 182 (10) | 281 (7) | 931 (33) |
| SA + SA | 158 (9) | 155 (4) | 0 (0) |
| Drug class | |||
| Cytotoxic chemotherapy* | 320 (17) | 1447 (36) | 1685 (61) |
| Epigenetic† | 202 (10) | 708 (18) | 17 (1) |
| Antibody-drug conjugate‡ | 135 (7) | 244 (6) | 66 (2) |
| Therapeutic antibodies§ | 374 (19) | 437 (11) | 0 (0) |
| SMi‖ | 460 (24) | 503 (13) | 83 (3) |
| IMIDs¶ | 38 (2) | 191 (5) | 0 (0) |
| Other# | 180 (9) | 212 (5) | 0 (0) |
| Combination | 225 (12) | 248 (6) | 931 (33) |
| Calendar period of publication | |||
| Before 2009 | 98 (5) | 375 (10) | 33 (1) |
| 2009-2015 | 507 (28) | 1603 (42) | 86 (3) |
| 2016 and after | 1186 (66) | 1840 (48) | 2663 (96) |
| Treatment setting | |||
| Upfront** | 256 (14) | 1205 (32) | 2482 (89) |
| Relapsed | 1498 (84) | 2439 (64) | 300 (11) |
| Upfront + relapsed | 37 (2) | 174 (5) | 0 (0) |
| . | Phase I (n = 60) No. (%) . | Phase II (n = 95) No. (%) . | Phase III (n = 23) No. (%) . |
|---|---|---|---|
| Treatment group | |||
| Novel SA | 1258 (70) | 2067 (54) | 277 (10) |
| CC | 193 (11) | 1315 (34) | 1574 (57) |
| SA + CC | 182 (10) | 281 (7) | 931 (33) |
| SA + SA | 158 (9) | 155 (4) | 0 (0) |
| Drug class | |||
| Cytotoxic chemotherapy* | 320 (17) | 1447 (36) | 1685 (61) |
| Epigenetic† | 202 (10) | 708 (18) | 17 (1) |
| Antibody-drug conjugate‡ | 135 (7) | 244 (6) | 66 (2) |
| Therapeutic antibodies§ | 374 (19) | 437 (11) | 0 (0) |
| SMi‖ | 460 (24) | 503 (13) | 83 (3) |
| IMIDs¶ | 38 (2) | 191 (5) | 0 (0) |
| Other# | 180 (9) | 212 (5) | 0 (0) |
| Combination | 225 (12) | 248 (6) | 931 (33) |
| Calendar period of publication | |||
| Before 2009 | 98 (5) | 375 (10) | 33 (1) |
| 2009-2015 | 507 (28) | 1603 (42) | 86 (3) |
| 2016 and after | 1186 (66) | 1840 (48) | 2663 (96) |
| Treatment setting | |||
| Upfront** | 256 (14) | 1205 (32) | 2482 (89) |
| Relapsed | 1498 (84) | 2439 (64) | 300 (11) |
| Upfront + relapsed | 37 (2) | 174 (5) | 0 (0) |
IMIDs, immunomodulatory drugs.
Cytotoxic chemotherapy arm included anthracycline-, ifosfamide-, gemcitabine-, and platinum-based treatments.
Epigenetic modifiers included histone deacetylase inhibitor (romidepsin, belinostat, chidamide), DNA methyltransferase inhibitor (azacytidine and decitabine), and EZH1/2 inhibitor (tazemetostat and valmetostat).
Antibody-drug conjugates included brentuximab vedotin and camidanlumab tesirine.
Therapeutic antibodies included alemtuzumab, nivolumab, pembrolizumab, durvalumab, avelumab, and anti-CD47 monoclonal antibody TTI621 and TTI622.
SMis included inhibitor of PI3K/AKT/mTOR, JAK/STAT, ALK (duvelisib, tenalisib, everolimus, ruxolitinib, cerdulatinib, crizotinib), aurora kinase (alisertib), farnesyl transferase, and proteosome pathways (tipifarnib, fenritinide, bortezomib).
IMIDs included cereblon inhibitors (lenalidomide and CPI 818).
Drugs in the “other” category included: ixazomib, avadomide, E777, darinaparsin, RH IL-15, valganciclovir, denileukin, bortezemib, carfilzomib, selinexor, 13 cis-retinoic acid, and interferon α.
Although data were collected for these trials, newly diagnosed patients were not included in the overall meta-analysis and subgroup analyses.